Anti-CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis. Palazzo L, Clarelli F, Surano M, Giordano A, Moiola L, Clinical SanRaf MS Study Group, Rocca MA, Filippi M, Esposito F Eur J Neurol. 2026 Oct; 33(10):e70771. PMID: 42867409. Abstract CommentRecommendBookmarkWatch
